Skip to main content

Advertisement

SpringerLink
Log in

Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Adults

  • Acute Lymphocytic Leukemias (K Ballen, Section Editor)
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

The majority of adults with acute lymphoblastic leukemia will achieve a first complete remission (CR). However relapse is the most common cause of treatment failure. Outcomes after relapse remain poor, with long-term survival in the order of 10 %. Treatment decisions made at the time of first complete remission are thus critical to ensuring long-term survival. Allogeneic hematopoietic cell transplant (HCT) is effective at preventing relapse in many transplant recipients but is also associated with significant treatment related morbidity and mortality. Alternatively, ongoing systemic chemotherapy offers lower toxicity at the expense of increased relapse rates. Over the past decades, both the safety of transplant and the efficacy of non-transplant chemotherapy have improved. Emerging data show substantially improved outcomes for young adults treated with pediatric-inspired chemotherapy regimens that question the role of HCT in the upfront setting. In this review, we review the data supporting the role of allogeneic transplantation in adult acute lymphoblastic leukemia (ALL), and we propose a therapeutic algorithm for upfront therapy of adults with ALL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Pulte D, Gondos A, Brenner H. Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood. 2009;113(7):1408–11. doi:10.1182/blood-2008-06-164863.

    Article  CAS  PubMed  Google Scholar 

  2. Kantarjian H, Thomas D, O’Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101(12):2788–801. doi:10.1002/cncr.20668.

    Article  CAS  PubMed  Google Scholar 

  3. Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106(12):3760–7. doi:10.1182/blood-2005-04-1623.

    Article  CAS  PubMed  Google Scholar 

  4. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation. Blood. 2008;111(4):1827–33. doi:10.1182/blood-2007-10-116582. The MRC/ECOG trial is the largest donor/no-donor study of alloHCT in ALL and helped establish alloHCT as standard of care.

    Article  CAS  PubMed  Google Scholar 

  5. Hoelzer D, Thiel E, Löffler H, et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood. 1988;71(1):123–31. http://www.ncbi.nlm.nih.gov/pubmed/3422030. Accessed January 29, 2016.

    CAS  PubMed  Google Scholar 

  6. Le Q-H, Thomas X, Ecochard R, et al. Initial and late prognostic factors to predict survival in adult acute lymphoblastic leukaemia. Eur J Haematol. 2006;77(6):471–9. doi:10.1111/j.1600-0609.2006.00753.x.

    Article  PubMed  Google Scholar 

  7. Patel B, Rai L, Buck G, et al. Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. Br J Haematol. 2010;148(1):80–9. doi:10.1111/j.1365-2141.2009.07941.x.

    Article  CAS  PubMed  Google Scholar 

  8. Gökbuget N, Kneba M, Raff T, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood. 2012;120(9):1868–76. doi:10.1182/blood-2011-09-377713.

    Article  PubMed  Google Scholar 

  9. Nagafuji K, Miyamoto T, Eto T, et al. Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study). J Hematol Oncol. 2013;6:14. doi:10.1186/1756-8722-6-14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Ravandi F, Jorgensen JL, O’Brien SM, et al. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2016;172(3):392–400. doi:10.1111/bjh.13834.

    Article  CAS  PubMed  Google Scholar 

  11. Ravandi F, Jorgensen JL, Thomas DA, et al. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013;122(7):1214–21. doi:10.1182/blood-2012-11-466482.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Zhou Y, Slack R, Jorgensen JL, et al. The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2014;14(4):319–26. doi:10.1016/j.clml.2014.01.002.

    Article  PubMed  Google Scholar 

  13. Bar M, Wood BL, Radich JP, et al. Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia. Leuk Res Treatment. 2014;2014:421723. doi:10.1155/2014/421723.

    PubMed  PubMed Central  Google Scholar 

  14. Tucunduva L, Ruggeri A, Sanz G, et al. Impact of minimal residual disease on outcomes after umbilical cord blood transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia: an analysis on behalf of Eurocord, Cord Blood Committee and the Acute Leukaemia working party of. Br J Haematol. 2014;166(5):749–57. doi:10.1111/bjh.12970.

    Article  PubMed  Google Scholar 

  15. Ribera J-M, Oriol A, Morgades M, et al. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA. J Clin Oncol. 2014;32(15):1595–604. doi:10.1200/JCO.2013.52.2425. This is the first trial to direct assignment of alloHCT based on MRD status affter induction chemotherapy. Overall survival was improved for those who achieved MRD negative status and were treated with chemotherapy only.

    Article  CAS  PubMed  Google Scholar 

  16. Dhédin N, Huynh A, Maury S, et al. Blood. 2015;125(16):2486–96. doi:10.1182/blood-2014-09-599894. quiz 2586. This study also demonstrates the prognostic significance of MRD status and showed that only patients with MRD positive disease derived benefit from alloHCT.

  17. Terwey TH, Hemmati PG, Nagy M, et al. Comparison of chimerism and minimal residual disease monitoring for relapse prediction after allogeneic stem cell transplantation for adult acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2014;20(10):1522–9. doi:10.1016/j.bbmt.2014.05.026.

    Article  PubMed  Google Scholar 

  18. Logan AC, Vashi N, Faham M, et al. Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival. Biol Blood Marrow Transplant. 2014;20(9):1307–13. doi:10.1016/j.bbmt.2014.04.018.

    Article  CAS  PubMed  Google Scholar 

  19. Thiebaut A, Vernant JP, Degos L, et al. Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hematol Oncol Clin North Am. 2000;14(6):1353–66. x. http://www.ncbi.nlm.nih.gov/pubmed/11147227. Accessed January 31, 2016.

    Article  CAS  PubMed  Google Scholar 

  20. Gupta V, Richards S, Rowe J. Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis. Blood. 2013;121(2):339–50. doi:10.1182/blood-2012-07-445098.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Hocking J, Schwarer AP, Gasiorowski R, et al. Excellent outcomes for adolescents and adults with acute lymphoblastic leukemia and lymphoma without allogeneic stem cell transplant: the FRALLE-93 pediatric protocol. Leuk Lymphoma. 2014;55(12):2801–7. doi:10.3109/10428194.2014.894191.

    Article  CAS  PubMed  Google Scholar 

  22. DeAngelo DJ, Stevenson KE, Dahlberg SE, et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015;29(3):526–34. doi:10.1038/leu.2014.229.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Lepretre S, Touzart A, Vermeulin T, et al. Pediatric-like acute lymphoblastic leukemia therapy in adults with lymphoblastic lymphoma: the GRAALL-LYSA LL03 study. J Clin Oncol. 2015. doi:10.1200/JCO.2015.61.5385.

    PubMed  Google Scholar 

  24. Seftel MD, Neuberg D, Zhang M-J, et al. Pediatric-inspired therapy compared to allografting for Philadelphia chromosome negative adult ALL in first complete remission. Am J Hematol. 2015. doi:10.1002/ajh.24285. This study demonstrates the improved outcomes for young adults treated with pediatric inspired chemotherapy protocols. A retrospective comparison with contemporaneous matched controls from the CIBMTR database demonstrated improved outcomes for those treated with chemotherapy alone.

    PubMed  Google Scholar 

  25. Liew E, Atenafu EG, Schimmer AD, et al. Outcomes of adult patients with relapsed acute lymphoblastic leukemia following frontline treatment with a pediatric regimen. Leuk Res. 2012;36(12):1517–20. doi:10.1016/j.leukres.2012.08.019.

    Article  PubMed  Google Scholar 

  26. Kako S, Kanamori H, Kobayashi N, et al. Outcome after first relapse in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia. Br J Haematol. 2013;161(1):95–103. doi:10.1111/bjh.12225.

    Article  PubMed  Google Scholar 

  27. Thomas X, Boiron J-M, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004;22(20):4075–86. doi:10.1200/JCO.2004.10.050.

    Article  CAS  PubMed  Google Scholar 

  28. Hunault M, Harousseau J-L, Delain M, et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood. 2004;104(10):3028–37. doi:10.1182/blood-2003-10-3560.

    Article  CAS  PubMed  Google Scholar 

  29. Ram R, Gafter-Gvili A, Vidal L, et al. Management of adult patients with acute lymphoblastic leukemia in first complete remission: systematic review and meta-analysis. Cancer. 2010;116(14):3447–57. doi:10.1002/cncr.25136.

    Article  PubMed  Google Scholar 

  30. Daver N, Thomas D, Ravandi F, et al. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica. 2015;100(5):653–61. doi:10.3324/haematol.2014.118588.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Ravandi F, O’Brien SM, Cortes JE, et al. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015;121(23):4158–64. doi:10.1002/cncr.29646.

    Article  CAS  PubMed  Google Scholar 

  32. Kim D-Y, Joo Y-D, Lim S-N, et al. Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. Blood. 2015;126(6):746–56. doi:10.1182/blood-2015-03-636548.

    Article  CAS  PubMed  Google Scholar 

  33. Tanguy-Schmidt A, Rousselot P, Chalandon Y, et al. Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study. Biol Blood Marrow Transplant. 2013;19(1):150–5. doi:10.1016/j.bbmt.2012.08.021.

    Article  CAS  PubMed  Google Scholar 

  34. Wetzler M, Watson D, Stock W, et al. Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance). Haematologica. 2014;99(1):111–5. doi:10.3324/haematol.2013.085811.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Giebel S, Labopin M, Gorin NC, et al. Improving results of autologous stem cell transplantation for Philadelphia-positive acute lymphoblastic leukaemia in the era of tyrosine kinase inhibitors: a report from the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Eur J Cancer. 2014;50(2):411–7. doi:10.1016/j.ejca.2013.08.027.

  36. Chalandon Y, Thomas X, Hayette S, et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 2015;125(24):3711–9. doi:10.1182/blood-2015-02-627935. This study demonstrates the feasability of reduced intensity chemotherapy regimens for older adults with Ph+ALL who are treated with tyrosine kinase inhibitors. Outcomes were similar for patients treated with autoHCT or alloHCT among patients who achieved major molecular response.

    Article  CAS  PubMed  Google Scholar 

  37. Pfeifer H, Wassmann B, Bethge W, et al. Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. Leukemia. 2013;27(6):1254–62. doi:10.1038/leu.2012.352.

    Article  CAS  PubMed  Google Scholar 

  38. Marks DI, Woo KA, Zhong X, et al. Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission: a comparison with allografts from adult unrelated donors. Haematologica. 2014;99(2):322–8. doi:10.3324/haematol.2013.094193.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Matsumura T, Kami M, Yamaguchi T, et al. Allogeneic cord blood transplantation for adult acute lymphoblastic leukemia: retrospective survey involving 256 patients in Japan. Leukemia. 2012;26(7):1482–6. doi:10.1038/leu.2012.11.

    Article  CAS  PubMed  Google Scholar 

  40. Tucunduva L, Ruggeri A, Sanz G, et al. Risk factors for outcomes after unrelated cord blood transplantation for adults with acute lymphoblastic leukemia: a report on behalf of Eurocord and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2014;49(7):887–94. doi:10.1038/bmt.2014.72.

    Article  CAS  PubMed  Google Scholar 

  41. Yan C-H, Jiang Q, Wang J, et al. Superior survival of unmanipulated haploidentical hematopoietic stem cell transplantation compared with chemotherapy alone used as post-remission therapy in adults with standard-risk acute lymphoblastic leukemia in first complete remission. Biol Blood Marrow Transplant. 2014;20(9):1314–21. doi:10.1016/j.bbmt.2014.04.011.

    Article  PubMed  Google Scholar 

  42. Sun Y-Q, Wang J, Jiang Q, et al. Haploidentical hematopoietic SCT may be superior to conventional consolidation/maintenance chemotherapy as post-remission therapy for high-risk adult ALL. Bone Marrow Transplant. 2015;50(1):20–5. doi:10.1038/bmt.2014.195.

    Article  PubMed  Google Scholar 

  43. Bachanova V, Marks DI, Zhang M-J, et al. Ph+ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease. Leukemia. 2014;28(3):658–65. doi:10.1038/leu.2013.253.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Eom K-S, Shin S-H, Yoon J-H, et al. Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission. Am J Hematol. 2013;88(8):634–41. doi:10.1002/ajh.23465.

    Article  CAS  PubMed  Google Scholar 

  45. Marks DI, Wang T, Pérez WS, et al. The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. Blood. 2010;116(3):366–74. doi:10.1182/blood-2010-01-264077.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Mohty M, Labopin M, Volin L, et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2010;116(22):4439–43. doi:10.1182/blood-2010-02-266551.

    Article  CAS  PubMed  Google Scholar 

  47. Mohty M, Labopin M, Tabrizzi R, et al. Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Haematologica. 2008;93(2):303–6. doi:10.3324/haematol.11960.

    Article  PubMed  Google Scholar 

  48. Weisdorf D, Bishop M, Dharan B, et al. Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: comparative toxicity and outcomes. Biol Blood Marrow Transplant. 2002;8(4):213–20. http://www.ncbi.nlm.nih.gov/pubmed/12014810. Accessed January 31, 2016.

    Article  PubMed  Google Scholar 

  49. Kantarjian H, Thomas D, Jorgensen J, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013;119(15):2728–36. doi:10.1002/cncr.28136.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. DeAngelo DJ, Stelljes M, Martinelli G, et al. Efficacy and safety of inotuzumab ozogamicin (INO) vs standard of care (SOC) in salvage 1 or 2 patients with acute lymphoblastic leukemia (ALL): an ongoing global phase 3 study. Late breaking abstract LB2073. Haematologica. 2015. http://learningcenter.ehaweb.org/eha/2015/20th/103387/daniel.deangelo.efficacy.and.safety.of.inotuzumab.ozogamicin.(ino).vs.standard.html?f=p3m3. Accessed February 5, 2016.

  51. Topp MS, Gökbuget N, Zugmaier G, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32(36):4134–40. doi:10.1200/JCO.2014.56.3247.

    Article  CAS  PubMed  Google Scholar 

  52. Topp MS, Gökbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57–66. doi:10.1016/S1470-2045(14)71170-2.

    Article  CAS  PubMed  Google Scholar 

  53. Zugmaier G, Gökbuget N, Klinger M, et al. Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment. Blood. 2015;126(24):2578–84. doi:10.1182/blood-2015-06-649111.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Maude SL, Teachey DT, Porter DL, Grupp SA. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015;125(26):4017–23. doi:10.1182/blood-2014-12-580068.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Maude SL, Shpall EJ, Grupp SA. Chimeric antigen receptor T-cell therapy for ALL. Hematology Am Soc Hematol Educ Program. 2014;2014(1):559–64. doi:10.1182/asheducation-2014.1.559.

    PubMed  Google Scholar 

  56. Amrolia PJ, Pule M. Chimeric antigen receptor T cells for ALL. Lancet. 2015;385(9967):488–90. doi:10.1016/S0140-6736(14)61729-3.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Hematology/Oncology, Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada

    Craig Speziali, Kristjan Paulson & Matthew Seftel

  2. Department of Medical Oncology and Haematology, CancerCare Manitoba, 675 McDermott Avenue, Winnipeg, MB, R3E 0V9, Canada

    Kristjan Paulson & Matthew Seftel

Authors
  1. Craig Speziali
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kristjan Paulson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matthew Seftel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthew Seftel.

Ethics declarations

Conflict of Interest

Craig Speziali declares no potential conflicts of interest. Kristjan Paulson reports personal fees from Lundbeck Canada and Sanofi. Matthew Seftel reports a grant from Lundbeck Canada.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Acute Lymphocytic Leukemias

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Speziali, C., Paulson, K. & Seftel, M. Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Adults. Curr Hematol Malig Rep 11, 175–184 (2016). https://doi.org/10.1007/s11899-016-0317-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-016-0317-2

Keywords

Search

Navigation